International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Cancer is one of the leading causes of morbidity and mortality worldwide, with complex and multifactorial mechanisms that contribute to its development and progression. While genetic mutations and environmental factors play significant roles, there is increasing recognition that chronic inflammation is a key driver in the initiation, progression, and metastasis of cancer. Inflammation, typically viewed as a protective response to infection or injury, becomes maladaptive in the context of cancer. Chronic, low-grade inflammation in the tumor microenvironment (TME) facilitates tumorigenesis, promotes immune evasion, and supports cancer cell survival and metastasis. As researchers continue to unravel the intricate relationship between inflammation and cancer, targeting inflammatory pathways has emerged as a promising strategy for improving cancer treatment efficacy. This article explores the role of inflammation in cancer development, the underlying molecular mechanisms, and current therapeutic approaches aimed at targeting inflammatory pathways to improve treatment outcomes [1].

Description

The role of inflammation in cancer

Chronic inflammation is a key contributor to the cancer process. It provides a favorable environment for tumor cells to thrive, grow, and spread. The role of inflammation in cancer can be broken down into several key areas:

Chronic inflammation and tumor initiation: Chronic inflammation can lead to DNA damage and mutations, a crucial step in cancer initiation. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), activate signaling pathways that induce the production of reactive oxygen species (ROS) and other inflammatory mediators, which cause cellular damage. Over time, this damage can accumulate, leading to genomic instability, mutations, and the formation of tumors. Additionally, inflammation can disrupt normal tissue repair mechanisms, further increasing the likelihood of cancer initiation.

Inflammation and tumor promotion: Once tumors are established, chronic inflammation supports tumor promotion by stimulating angiogenesis (the formation of new blood vessels) and providing a continuous supply of nutrients and oxygen to the growing tumor mass [2]. Inflammatory cells such as tumor-associated macrophages (TAMs) and neutrophils secrete pro-angiogenic factors like vascular endothelial growth factor (VEGF), which facilitates the growth of new blood vessels. This promotes the expansion of the tumor and allows for its spread to distant organs. Furthermore, inflammatory cytokines can alter the extracellular matrix (ECM), enabling cancer cells to invade surrounding tissues and spread (metastasize).

Immune evasion and tumor immunosuppression: One of the hallmarks of cancer is its ability to evade immune surveillance. Inflammation can play a significant role in promoting immune evasion by altering the immune microenvironment of the tumor. Tumor cells and associated immune cells in the TME often produce cytokines and chemokines that suppress the activity of cytotoxic T cells and natural killer (NK) cells, which are responsible for detecting and killing cancer cells. Tumor-associated macrophages, for example, can polarize to an M2 phenotype, which is associated with immune suppression and the promotion of tumor progression. Inflammatory mediators, such as IL-10 and transforming growth factor-beta (TGF-β), further dampen anti-tumor immune responses, allowing tumors to evade detection and destruction [3].

Inflammation and metastasis: Chronic inflammation is also a key factor in metastasis, the spread of cancer cells from the primary tumor to distant organs. Inflammatory cytokines and immune cells create a permissive microenvironment that promotes the detachment of cancer cells from the primary tumor, their invasion into the bloodstream or lymphatic system, and their colonization of distant organs. This process is known as the metastatic cascade. For example, IL-6, a common inflammatory cytokine elevated in various cancers, plays a significant role in the epithelial-to-mesenchymal transition (EMT), a critical step in metastasis where cancer cells gain migratory and invasive properties. Inflammation also enhances the ability of circulating tumor cells to survive in the bloodstream and colonize new tissues.

Inflammation and chemotherapy resistance: Inflammatory signals within the TME can promote resistance to chemotherapy and other conventional cancer treatments. Many tumors rely on the activation of pro-survival signaling pathways, such as NF-κB and the JAK/STAT pathway, which are often triggered by inflammatory cytokines. These pathways confer resistance to cell death, allowing tumor cells to survive despite the cytotoxic effects of chemotherapy. Additionally, inflammation can impair the function of immune cells, limiting the effectiveness of immunotherapies [4]. Tumor-associated inflammation thus contributes to the challenge of overcoming resistance and achieving durable responses in cancer treatment.

Targeting inflammatory pathways in cancer treatment

Given the critical role of inflammation in cancer development and progression, targeting inflammatory pathways holds significant potential for improving treatment efficacy. Several strategies are currently being explored to modulate inflammation in the tumor microenvironment, either by inhibiting pro-inflammatory cytokines, blocking key inflammatory signaling pathways, or reprogramming immune cells within the TME. Some of these strategies include:

Cytokine inhibition: Several inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, have been implicated in promoting tumor growth, metastasis, and immune evasion. Targeting these cytokines with monoclonal antibodies or small molecules has shown promise in preclinical and clinical trials. For example, monoclonal antibodies against TNF-α, such as infliximab and adalimumab, are used to treat inflammatory diseases like rheumatoid arthritis and have demonstrated potential for reducing tumor growth in specific cancers. Similarly, targeting IL-6 signaling using monoclonal antibodies like tocilizumab has been explored in cancers associated with elevated IL-6 levels, such as multiple myeloma and ovarian cancer [5].

NF-κB pathway inhibition: The NF-κB pathway is a central regulator of inflammation and has been implicated in tumor survival, metastasis, and resistance to chemotherapy. Inhibiting this pathway can suppress the expression of inflammatory cytokines and survival factors in the TME, making tumor cells more susceptible to treatment. Several small-molecule inhibitors targeting components of the NF-κB pathway, such as IKKβ inhibitors, are under investigation [6]. Early-stage trials have shown promise in reducing tumor growth and overcoming chemotherapy resistance in various cancers.

Targeting the JAK/STAT pathway: The JAK/STAT pathway is another key mediator of inflammation and cancer progression. Activation of this pathway by inflammatory cytokines like IL-6 promotes tumor cell survival and immune evasion. Small molecules that inhibit JAK1/2 (such as ruxolitinib) are already approved for the treatment of certain hematological cancers and are being explored for solid tumors as well. Inhibiting this pathway has shown potential in reducing tumor growth and enhancing immune responses in cancer patients [7].

Reprogramming tumor-associated macrophages (TAMs): Tumor-associated macrophages are a critical component of the tumor microenvironment, and their polarization to an M2 phenotype promotes immune suppression and tumor progression. Reprogramming TAMs from an M2 to an M1 phenotype (which is anti-tumorigenic) is a promising therapeutic strategy. Several approaches are being developed to either directly target TAMs or modulate the signals that promote their M2 polarization. These strategies aim to shift the immune response in the TME from pro-tumorigenic to anti-tumorigenic, potentially enhancing the effectiveness of existing therapies [8].

Immune checkpoint inhibition: While immune checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 inhibitors have revolutionized cancer immunotherapy, their effectiveness is often limited by the presence of inflammation-induced immune suppression within the TME. Combining immune checkpoint inhibitors with anti-inflammatory agents that reduce immune suppression and inflammation may enhance the anti-tumor immune response and improve treatment outcomes [9]. For example, combining PD-1 inhibitors with cytokine inhibitors or NF-κB pathway blockers has shown promise in preclinical models.

Dietary and lifestyle interventions: In addition to pharmacological approaches, dietary and lifestyle interventions aimed at reducing systemic inflammation may complement conventional cancer therapies. Nutrients such as omega-3 fatty acids, curcumin, and resveratrol possess anti-inflammatory properties and have been shown to inhibit key inflammatory pathways. Incorporating these compounds into cancer treatment regimens may help reduce inflammation and improve therapeutic outcomes [10].

Conclusion

Inflammation is a critical driver of cancer development, progression, and metastasis. The persistent low-grade inflammation in the tumor microenvironment creates conditions that support tumor cell survival, immune evasion, and resistance to treatment. Understanding the mechanisms that link inflammation to cancer has paved the way for the development of targeted therapies aimed at modulating inflammatory pathways. Current strategies, including cytokine inhibition, NF-κB and JAK/STAT pathway inhibitors, reprogramming immune cells, and immune checkpoint blockade, hold great promise in enhancing the efficacy of cancer treatments. As we continue to unravel the complexities of inflammation and cancer, the combination of anti-inflammatory agents with traditional cancer therapies may offer a more effective and personalized approach to cancer treatment, ultimately improving patient outcomes and survival rates.

Acknowledgement

None

Conflict of Interest

None

References

1. Paucek RD, Baltimore D, Li G (2019) The cellular immunotherapy revolution: arming the immune system for precision therapy. Trends immunol 40: 292-309.

Indexed at, Google Scholar, Crossref

2. Mackenzie NJ, Nicholls C, Templeton AR, Perera MP, Jeffery PL, et al. (2022) Modelling the tumor immune microenvironment for precision immunotherapy. Clinical & Translational Immunology 11: e1400.

Indexed at, Google Scholar, Crossref

3. Obradovic A (2023) Precision immunotherapy. Science 379: 654-655.

Indexed at, Google Scholar, Crossref

4. Rossi JF, Céballos P, Lu ZY (2019) Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Communications 39: 34.

Indexed at, Google Scholar, Crossref

5. Widodo SS, Hutchinson RA, Fang Y, Mangiola S, Neeson PJ, et al. (2021) Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunol Immunother 70: 1811-1820.

Indexed at, Google Scholar, Crossref

6. Mandal R, Chan TA (2016) Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discovery 6: 703-713.

Indexed at, Google Scholar, Crossref

7. Lee JK, Priceman SJ (2019) Precision medicine-enabled cancer immunotherapy. Cancer Treat Res 178: 189-205.

Indexed at, Google Scholar, Crossref

8. Mukherjee S (2019) Genomics-guided immunotherapy for precision medicine in cancer. Cancer Biother Radiopharm 34: 487-497.

Indexed at, Google Scholar, Crossref

9. Du Y, Qi Y, Jin Z, Tian J (2019) Noninvasive imaging in cancer immunotherapy: The way to precision medicine. Cancer letters 466: 13-22.

Indexed at, Google Scholar, Crossref

10. Lau D, Bobe AM, Khan AA (2019) RNA sequencing of the tumor microenvironment in precision cancer immunotherapy. Trends cancer 5: 149-156.

Indexed at, Google Scholar, Crossref